MedTrace Logo

Phase I Study of HXN6005 in Adult Healthy Participants

NCT07449741 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-04-24

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetic characteristics and pharmacodynamics of HXN6005 in Healthy Participants.

Researchers will compare HXN6005 to a placebo (a look-alike substance that contains no drug).

Participants will take a single dose of HXN6005 or placebo on Day 1, and visit the clinic for followup and tests per the protocol scheme.

Conditions

  • Healthy Volunteers (HV)

Interventions

DRUG

HXN6005

participants will receive a single subcutaneous dose of HXN6005 at escalating dose levels in Cohort 1-4,

DRUG

Placebo

Participants will receive matching placebo across cohorts 1-4 of the study.

Sponsors & Collaborators

  • Helixon Biotechnology (Suzhou) Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-27
Primary Completion
2027-03-13
Completion
2027-03-13

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07449741 on ClinicalTrials.gov